ASPIRE PHARMA LTD

One to watch in the UK Healthcare Advertising industry this month.

The following findings are taken from the Plimsoll Analysis and show why ASPIRE PHARMA LTD is one to watch in the UK Healthcare Advertising industry this month. According to the latest Plimsoll Analysis they are exceptional because of:

Their excellent financial health

The Plimsoll Analysis of ASPIRE PHARMA LTD shows:

The Plimsoll Chart is high and rising indicating an improvement in financial strength, well above the industry average.
The company is the 3rd largest in the market
The company is the 6th most profitable
It is one of the strongest in the UK market

Their attractiveness as an acquisition

Along with the UK's 55 other leading Healthcare Advertising, ASPIRE PHARMA LTD has been rated on it acquisition attractiveness:

The company could command a price premium
It has been rated on 9 specific acquisition criteria
It does however have the resources to be on the lookout for acquisitions
6 companies are ripe for takeover according to the Plimsoll Analysis

Plus some of its other key achievements this year

The Plimsoll Analysis reveals the true performance of each company. Here are some other key findings for ASPIRE PHARMA LTD:

One of the 'Fastest Growing' companies.
Increasing sales and a healthy Plimsoll chart.
Pretax profits have risen 23% in the latest year.
One of the 'Most Profitable' companies.
Total sales have risen 16% in the latest year.
Listed in 'Pre-tax Profit Return on Owners Funds'.
Generates an excellent profit on total assets.
One of the best in terms of sales per employee.
The value of the company has increased in the latest year.
Latest sales are £114.96 million

6 Charts

The 6 charts measure sales growth, return on assets, profitability, debt, and cover for creditors. A rising line is good and a falling line is bad.

Company Details

The page shows the registered office, auditor's details and the key board member.

Plimsoll Chart

The Plimsoll Chart is the overall measure of the change in a companies financial performance. A high and rising line indicates the company is STRONG.

Company Summary

Written commentary is provided detailing key findings including current ranking and any special achievements.

Financial Data

5 years' worth of financial data is provided on each company.

Future Year

Projected Future Year – we estimate how the company could improve its overall value and financial stability.

SALES GROWTH

(% Change in Sales Year On Year)

TRADING STABILITY

(Sales Return On Total Assets)

RETAINED PROFITABILITY

(Retained Profit Return On Total Assets)

WORKING CAPITAL

(Repay Debt Without Selling Fixed Assets)

GEARING

(How Much is Owned By The Shareholders)

IMMEDIATE LIQUIDITY

(Immediate Cover For Trade Creditors)

PLIMSOLL CHART

(Overall Financial Health)

ASPIRE PHARMA LTD

Registration Number:	06828501	Website:	www.aspirepharma.co.uk
Incorporation Date:	24/02/2009	Audit. Fees:	££27,000
Last Annual Return:		Secretary:	Mr Gary David Buckley

Registered Address:	102 High Street, Godalming,
	Surrey.
	GU7 1DS

Directors

Mr Gary David Buckley (40 yrs)
Mr Jonathan Charles May (55 yrs)

Mr Richard Condon (49 yrs)

Development, registration, marketing and distribution of branded and generic pharmaceutical

products.

						PROPOSED YEAR

Period Ending	31-Dec-20	31-Dec-21	31-Dec-22	31-Dec-23	31-Dec-24	30-Dec-25
Weeks	52	52	52	52	52	52
£000
Total Sales	55560	62703	81729	99114	114959	135652
Directors Fees	248	1774	0	0	0	0
Gross Profit	26823	29390	35588	35876	44561	52582
Value Added	22280	23165	24437	25001	32058	45245
Trading Profit	19065	13392	20612	20320	24796	37475
Depreciation	55	68	76	99	104	125
Non-Trading Income	1	22	22	100	237	0
Total Interest Charges	1	0	0	0	0	0
Pretax Profit	19010	13346	20558	20321	24929	37350
Retained Proft (+ - Shareholders Funds)	9673	7543	1987	291	17292	14957

Fixed Assets	185	150	139	173	167	200
Intangibles	12742	12973	12310	13885	24127	28952
Intermediate Assets	0	0	0	0	26	31

Stocks	16609	15345	16753	22606	30857	36411
Debtors	6366	9702	13173	13398	16381	19330
Cash Or Equivalent	13535	22520	22753	27236	24806	35561
Total Current Assets	36510	47567	52679	63240	72044	91302
Creditors	6350	9197	8906	17494	19473	26425
Short Term Borrowing	97	0	0	0	5	0
Oth.Curr.Liabilities	4065	5050	8005	10276	9985	11982
Tot.Curr.Liabilities	10512	14247	16911	27770	29463	38407
Net Curr.Assets	25998	33320	35768	35470	42581	52895

Shareholders Funds	38687	46230	48217	48508	65800	80757
Total Loan Capital	0	0	0	0	0	0
Other Capital Employed	38926	46443	48217	49528	66901	1321
Tot.Capt.Employed	38926	46443	48217	49528	66901	82078

Pretax Profit Margin %	34.22	21.28	25.15	20.50	21.69	27.53
Sales Growth %	-6	13	30	21	16	18
Pretax Profit Growth %		-30	54	-1	23	50
Debtor Ratio Days	42	56	59	49	52	52
Creditor Ratio Days	42	53	40	64	62	71
Stock Turnover	3	4	5	4	4	4

Sales £000/Employee	958	995	1151	1255	1150	1265
Value Added £000/Empl.	384	368	344	316	321	423
Av. Remun. £000/Empl.	55	155	54	59	73	73
Total Empl. Remu. £000	3215	9773	3825	4681	7262	7770
Employees	58	63	71	79	100	107

Pretax Profit/Total Assets %	38	22	32	26	26	31

COMPANY SUMMARY

The Plimsoll Chart is high and rising indicating an improvement in financial strength, well above the industry average.
Total Sales have increased by 16.0% in the latest year, well above the industry average of -6.7%.
Sales per Employee is £1.1m which is well above the industry average of £139,000.
The company is ranked among the fastest growing in terms of sales growth in the latest year.
Pretax Profit Margin is 21.7% in the latest year, well above the industry average of 11.8%.
The Profitability chart shows a well above average pretax profit return on total assets in the latest year.
The company is among the Top 3 companies listed as a Best Trading Partner (see section 1c).
The company is among the Top 50 companies listed as a Fastest Growing Company (see section 2.1c).
The company is among the Top 4 in terms of Trading Profits.
The company is among the Top 12 Leaders in Efficiency.
The company is among the Top 50 companies listed under the Pretax Profit Return on Total Assets category (see section 3.4c).
The company is among the Top 6 in terms of Pretax Profit Return on Owners Funds.
The company is among the Top 31 companies listed under the Pretax Profits category (see section 3.2c).

Key Attractiveness features

Key reasons to accquire this company are highlighted

Acquisition Attractiveness Rating

Each company gets a 9 point takeover checklist designed to pick out targets with the most potential

Overall Rating Chart

This chart shows how attractive a company is. The higher the chart the better the takeover

Company Valuation

Each company is givenan overall value and a value after liabilities for each of the last 4 years

Company Trend

This chart shows the trend in a companies value over the past 4 years

Comments

A description of the factors affecting valuation and attractiveness is provided for each company

ASPIRE PHARMA LTD- ACQUISITION ATTRACTIVENESS ANALYSIS

COMPANY SUMMARY:

The company currently has £115m sales and made £24.9m, by following the proposal plan, sales would rise to £136m and profits would rise to £37.4m.

KEY ATTRACTIVENESS FEATURES:

ADD £115m TO SALES
ATTRACTIVE PRICE
FEW DIRECTORS

Acquisition Attractiveness Rating: ( Meets criteria Does not meet criteria)

Criteria

Sales growth above the industry average
Low financial rating
High gross earnings")
Low number of shareholders
Big difference between current and future value
Directors fees represent high proportion of profits
Average age of directors is high
Company is privately owned
Low number of directors

Acquisition Rating

HIGHLY ATTRACTIVE
WORTH CONSIDERING
UNATTRACTIVE

Company Valuation:

					♦
					Proposed Yr
Year end:	31-Dec-21	31-Dec-22	31-Dec-23	31-Dec-24	30-Dec-25
Total Sales (£000):	62703	81729	99114	114959	135652
Pretax Profits (£000):	13346	20558	20321	24929	37350
Total value (£000):	113660	145055	151167	195018	271674
Asset value (£000):	38170	42375	50062	71558	84924
Goodwill (£000):	75490	102680	101105	123460	186750
Liabilities (£000):	8060	5842	-1554	-5758	-4167
Equity value (£000):	121720	150897	149613	189260	267507

Total Value Formula: (Pretax Profit + Interest Payments - Non Trading Income + Directors Fees) * 5 plus
(Fixed Assets + Intangibles + Intermediate Assets + Stocks + Debtors)

Shareholders / Ownership:

APHL 2 LTD

Immediate Shareholder: APHL 2 LTD

Subsidiaries:

APIE LTD

ASPIRE PHARMA GMBH

CENOTE PHARMA LTD

CHARLWOOD PHARMA LTD

DERMATO LOGICAL LTD

Acquisition / Valuation Comments:

This company has been established 17 years.

The number of shareholders is low (1).

The value of the company has risen in each of the last 2 years.

The total value of the company is currently £195.0m including debts.

The equity value is high, indicating low levels of total liabilities.

The proposed year is based on achieving a 31% return on total assets.

The company's value would increase by 39% if the proposed business plan was followed.

Google search for more info:www.google.co.uk/search?q=ASPIRE+PHARMA

What is the Plimsoll Analysis?

The Plimsoll Analysis brings together 5 years of financial data on the UK's leading 55 Healthcare Advertising companies and produces a graphical and written study of their financial health, overall value and attractiveness for takeover. Once we have individually assessed the companies we categorise them based on different criteria. Our rankings are not available anywhere else and will show you:

The most profitable
The best acquisition
The best performers
The companies in Danger

The most improved
The cash rich
The fastest growing
The biggest threats

The loss makers
The most productive
The fastest shrinking
And much more

The analysis also splits the companies by region, size, turnover and much more giving you the most complete and convenient study of the market possible.

What can I do with it?

Since its launch in 1987, the Plimsoll Analysis has been used by senior decision makers to give them the inside track on what's going on in the Healthcare Advertising industry. We lay out our findings on each company using easy to understand charts and simple written statements so you can easily:

Benckmark your own performance
Pick out "hot" acquisition prospects

See what the STRONG are doing
Spot rivals heading for failure

Monitor up and coming threats
Keep up to date with changes

What do I get on each company?

On each company you will receive:

A unique financial health assessment
A 9 point acquisition checklist

A graphical performance rating
An independent valuation

An acquisition attractiveness rating
Written summary of key findings

How to Order the Plimsoll Analysis

There are 4 easy ways to order your copy of the brand new Plimsoll Analysis for the UK Healthcare Advertising Industry. Please choose from the following:

ONLINE: Click here to order via www.plimsoll.co.uk

EMAIL: Email enquiries@plimsoll.co.ukconfirming an invoicing address

TELEPHONE: Call +44 0 1642 626 470

FAX: Sign below and fax back to +44 0 1642 626410

Please complete the following and fax back to 01642 626410 or scan and email to enquiries@plimsoll.co.uk

Please choose your preferred option:

Snapshot PDF Report Only £350 (+VAT)

Online Industry Report (1 year access and free snapshot PDF included) Only £649 (+VAT)

Complete your invoicing details and sign to confirm

Name
Company Name
Invoice Email
Sign to confirm

Address
Email Address
Telephone
Date

DISCLAIMER This analysis is confidential and may be used by a customer of Plimsoll Publishing Limited only. The report should not be passed to or used or relied on by any other person. Plimsoll Publishing Limited cannot accept any liability to any other person who places reliance on this report. The report is based on information provided by the customer and in the public domain and has been produced for informational purposes only. The report should not be relied on by the customer in making investment or other decisions. With the exception of liability for Plimsoll's negligence resulting in personal injury, death and fraud, for which Plimsoll does not limit or exclude its liability, Plimsoll (a) excludes its liability for all indirect or consequential loss and (b) limits its liability in all other respects to a maximum of the amount paid by the customer for the report